Skip Navigation

Lotus to launch 3 oncology drugs in Taiwan starting the third quarter, envisaging broad oncology portfolio

01 July 2017

Lotus Pharmaceutical held a product launch seminar at Nangang Exhibition hall today during BioTaiwan 2017. Key opinion leaders including Dr. Shinn-Zong Lin from Hualian Tzu Chi Hospital, Dr. Ching-Liang Ho from Tri-Service General Hospital, and Dr. Jeng-Fong Chiou from TMU Taipei Cancer Center participated in sessions discussing the treatment and clinical behaviors of brain cancer, leukemia, and breast cancer patients with Lotus commercial team.

In the seminar, Lotus General Manager Jefferson Wang said that the Company will launch 3 oncology drugs in Taiwan this year, and they are the long-neglected generics “Ixempra (Ixabepilone for injection), Alvotinib (Imatinib 100mg/400mg film coated tablets), and the generic version of Xeloda Tablets (Capicetabine).” He also explained that the combined therapy of Ixempra and Capecitabine would significantly improve median progression-free survival compared to monotherapy, and Alvotinib should be the largest generic against the originator in Taiwan. “We are confident that Lotus is on its way of broad oncology portfolio builds which should position us well for long term growth.”

Lotus is committed to licensing in and launching generics that patients and doctors both find reliable to provide more options in oncology treatments. Taipei Municipal Wanfang Hospital Superintendent Gi-Shih Lien and Taipei Medical University Shuang Ho Hospital Superintendent Fei-Peng Lee both showed their support toward this initiative and attended the seminar for a brief speech.